PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22225965-2	2012	We explored symptomatic remission rate in patients treated with flexibly dosed paliperidone ER by 8 items of Positive and Negative Syndrome Scale (PANSS) and change of Personal and Social Performance (PSP) scale.	Paliperidone Palmitate	79-91	BPI fold containing family A member 2	Homo sapiens	168-199	
30758986-4	2019	RESULTS: During the 12-month study period significant improvement was registered in patients receiving both paliperidone palmitate and risperidone in the following scales: PANSS, PSP, CGI-I, and CGI-S.	Paliperidone Palmitate	108-130	BPI fold containing family A member 2	Homo sapiens	179-182	
30758986-5	2019	Patients receiving paliperidone palmitate had significantly greater improvement in PANSS, CGI-S, and PSP compared with the risperidone group.	Paliperidone Palmitate	19-41	BPI fold containing family A member 2	Homo sapiens	101-104	
28454922-0	2018	Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.	Paliperidone Palmitate	0-22	BPI fold containing family A member 2	Homo sapiens	88-119	
28454922-1	2018	OBJECTIVE: Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study.	Paliperidone Palmitate	34-56	BPI fold containing family A member 2	Homo sapiens	131-162	
28454922-1	2018	OBJECTIVE: Evaluate the effect of paliperidone palmitate once-monthly (PP1M) injectable on the specific functioning domains of the Personal and Social Performance (PSP) scale in patients with schizoaffective disorder (SCA) participating in a long-term study.	Paliperidone Palmitate	34-56	BPI fold containing family A member 2	Homo sapiens	164-167	
22225965-15	2012	CONCLUSIONS: Although the short-term nature of this study may limit the potential for assessing improvements in function, it is noteworthy that in the present short-term study significant improvements in patient personal and social functioning with paliperidone ER treatment were observed, as assessed by PSP scale.	Paliperidone Palmitate	249-261	BPI fold containing family A member 2	Homo sapiens	305-308